Evaluation of performance of quantiferon assay and tuberculin skin test in end stage renal disease patients receiving hemodialysis
|
|
- Barrie Rose
- 5 years ago
- Views:
Transcription
1 NEW MICROBIOLOGICA, 34, , 2011 Evaluation of performance of quantiferon assay and tuberculin skin test in end stage renal disease patients receiving hemodialysis Emin Maden 1, T. Taha Bekci 2, Recep Kesli 3, Huseyin Atalay 4, Turgut Teke 1, Yalcın Solak 4, Suleyman Turk 4, Kursat Uzun 1, Ramazan Koylu 5 1 Selcuk University, Meram Medical Faculty, Department of Pulmonary Medicine; 2 Konya Research and Education Hospital, Department of Pulmonary Disease; 3 Konya Research and Education Hospital, Microbiology Laboratory, 4 Selcuk University, Meram Medical Faculty, Department of Nephrology; 5 Konya Research and Education Hospital Department of Emergency, Konya, Turkey SUMMARY Purpose: End stage renal disease (ESRD) cases are associated with increased risk of tuberculosis. There is no gold standard method for detecting latent tuberculosis infection (LTBI) in ESRD. The aim of the present study was to analyze the performance of the tuberculin skin test (TST) and QuantiFERON-TB Gold in tube (QFT-G) in cases receiving hemodialysis (HD). Methods: The TST and QFT-G were prospectively performed in 96 ESRD cases undergoing HD. The agreement of the QFT-G and TST was assessed in two TST cut off values (10 mm and 5 mm) in Bacille Calmette Guérin (BCG) vaccinated and non-vaccinated cases. Results: Of 96 cases 67 were BCG vaccinated and 29 were BCG non-vaccinated. QFT-G was positive in 39.6% cases and indeterminate in 3.1%. TST was positive in 43.8% of cases in cut off value of 10 mm and positive in 58.3% of cases in cut off value of 5 mm. Agreement between TST and QFT-G results was fair in both BCG vaccinated and non-vaccinated cases in either cut off values, except in cut off value of 10 mm in BCG vaccinated cases in which the agreement was moderate. Conclusion: The agreement between QFT-G and TST test is fair and there is no significant difference in both cut off values of TST in screening of LTBI in ESRD cases receiving HD. KEY WORDS: Tuberculosis, Hemodialysis, Quantiferon test Received November 24, 2011 Accepted April 18, 2011 Tuberculosis (TB) remains a major health problem not only in developing countries but in developed countries as well. The incidence of TB is higher in end-stage renal disease (ESRD) patients owing to impaired host defense mechanisms, particularly immune suppression, which is more important in endemic regions (Hussein et al., 2003, Cengiz et al., 1996, Mitwalli et al., 1991, Andrew et al., Kür at et al., 2001). Diagnosis is difficult Corresponding author Recep Kesli Konya Research and Education Hospital Microbiology Laboratory Meram, Konya, Turkey recepkesli@yahoo.com and delayed since extra pulmonary involvement is more common than isolated pulmonary involvement, and nonspecific symptoms mimicking uremia are seen frequently. Uremia itself is known to cause impaired cellular immunity, which is the major host defense mechanism against TB infection (Kurtz et al., 1986). Moreover, patients on hemodialysis (HD) are at increased risk of developing active tuberculosis after primary infection, activation of quiescent disease, or reactivation of old TB infection. Nosocomial transmission of TB has also been reported in patients under long-term dialysis (Hickstein et al., 2003). Diagnosis of TB in immune-compromised patients and patients on HD could be difficult and
2 352 E. Maden, T. Bekci, R. Kesli, H. Atalay, T. Teke, Y. Solak, S. Turk, K. Uzun often missed. This is due to vague presentation with inconclusive chest X-rays and negative tuberculin skin tests (TST). The TST remains the standard method for identifying TB infection in screening of LTBI in chronic renal failure patients and in patients receiving hemodialysis. In fact, ESRD is known to be a risk factor for skin test anergy; although the rate of anergy is quite variable, recent reports suggest that about 32% to 40% of HD patients are anergic (Ravi Shankar et al., 2005, Woeltje et al., 1998, Smirnoff et al., 1998). This indicates that additional clinical testing is needed in dialysis patients for the presence of tuberculosis beyond the use of a routine TST. A new diagnostic method, QuantiFERON-TB gold in tube is an in vitro test for Mycobacterium (M) TB infection. It measures interferon gamma (IFN-γ) secreted by T cells which are stimulated with mixtures of synthetic peptides including the early secretary antigenic target-6 (ESAT-6) and culture filtrate protein 10 (CFP-10) that are specific to M. TB. After incubation of whole blood with the mixture of synthetic peptides, an ELISA detects the release of IFN-γ from lymphocytes. Because the target peptides are secreted by M. TB and M. bovis, but not by strains present in the Bacille Calmette Guérin (BCG) vaccine and by most nontuberculous mycobacteria, QFT-G may correlate better with exposure to M. TB than the TST. In this scenario, blood samples would be taken from the patient and incubated with mycobacterial antigens specific for M. TB complex strains but not for the BCG vaccine strain. T lymphocytes within the blood sample produce IFN-γ as a marker of infection or active TB. Since M. TB is an intracellular pathogen, assessment of whether a patient s T cells have been exposed to and sensitized by antigens specific to M. TB, may provide an alternative approach to diagnosis. IFN-γ assays have several advantages over TST (Amicosante et al., 2010). Its results can be available in 24 hours after testing and no return visit is required. Automated testing has the advantage of reducing reader bias as its interpretation is objective. A booster phenomenon does not occur and therefore screening of people who are repeatedly exposed to TB (e.g. healthcare workers) becomes feasible. Patients with impaired immune function are one of the most important targets for the screening of LTBI because of the high risk of progression to active TB. QFT-G tests have been studied in various groups of immunocompromised subjects (HIV infection, immuno-suppressed hematology patients, auto-immune diseases, silicosis) (Jones et al., 2007, Luetkemeyer et al., 2007, Leung et al., 2008, Menzies et al., 2007,Kobashi et al., 2007, Piana et al., 2006.). Although responses to QFT-G tests are slightly reduced in immunosuppressed subjects, when compared with immuno-competent individuals, positivity rate of QFT-G test is substantially higher than that of TST (Menzies et al., 2007). However, there is no sufficient data on QFT-G test use in screening of LTBI in chronic renal failure patients and in patients receiving hemodialysis. There are few studies evaluating the value of QFT-G test in LTBI in these cases and also investigating the agreement between QFT-G test and TSTs. In this study we aimed to analyze the performance of the TST and QFT-G in cases with ESRD cases receiving hemodialysis and to evaluate the agreement of these tests in BCG vaccinated and non-vaccinated cases. Patients with ESRD who underwent HD for more than 3 months were enrolled in this study prospectively in Konya, Turkey. Approval of Institutional Review Board was provided and all participants gave written informed consent. Patients charts were reviewed for demographics (age, and sex), etiology of ESRD, duration of HD and past medical history. Efficiency of dialysis was measured using urea reduction ratio (URR) and depict delivered dose of dialysis (Kt/V). Patients with positive TST or QFT-G test were submitted for evaluation of active TB disease and isoniazid prophylaxis was recommended to those patients in whom no active disease was determined but was positive in either of the two assays. TST was performed on the volar aspect of the forearm by the Mantoux method using 0.1 ml (5 tuberculin units) of PPD Tuberculin Tween 80 (BB-NCIPD Ltd. Sofia, Bulgaria). Induration was measured after hours using the ballpoint pen method. TST response was scored as positive if induration diameter was equal or >10 mm (the recommended TST induration cut-off point among persons with chronic renal failure (American Thoracic Society and the Centers for Disease Control and Prevention). To determine
3 Quantiferon assay and tuberculin skin test in end stage renal disease patients 353 the development of booster phenomenon, the patients with a reaction of less than 10 mm induration to the initial TST were given a second tuberculin test 1 to 2 weeks later. The booster phenomenon was defined as positive if induration from the second test was 10 mm or more and measured at least 6 mm more than that for the TST-1. These results were defined as TST 1. A secondary evaluation, by accepting TST results as positive if the induration was >5 mm (the recommended TST induration cut-off point for patients with organ transplants and other immunosuppressed patients (American Thoracic Society and the Centers for Disease Control and Prevention)), was done and these results were defined as TST 2. Interferon-γ release assays, QFT-G test, were performed according to the manufacturer s instructions (Cellestis Ltd., Carnegie, Victoria, Australia). A result of 0.35 IU/mL of IFN-γ in the TB antigen tube minus the negative control tube was considered a positive result. If the level was less than this and the mitogen control was positive ( 0.5 IU/mL), a negative result was recorded. If the level in both the TB antigen and mitogen tube was less than the threshold for positive, or the level in the nil tube was >8.0 IU/mL, then an indeterminate result was recorded (according to the manufacturer s instructions). Results across the two primary modalities in the analysis (QFT- G test and TST) were compared using the Chi-squared test. Multivariate analysis was also performed to analyze the influence of age, vaccination, sex and other confounding factors to the TST and QFT- G test. Agreement between tests was qualified according to kappa statistics. Kappa Agreement was interpreted as follows: κ=<0: Less than chance agreement, κ= : Slight (poor) agreement, κ= : Fair agreement, κ= : Moderate agreement, κ= : Substantial agreement, κ= : Almost perfect agreement (Viera et al., 2005). P value <0.05 was considered statistically significant. A total of 96 (49 male and 47 female) ESRD cases receiving hemodialysis were enrolled to study. The mean age of the patients was 54.81± The number of cases who were BCG vaccinated was 67 (69.8%) and the median duration of dialysis was (3-240) months. QFT-G test result was positive in 38 (39.6%) cases and it was negative in 55 (57.3%) cases. In 3 (3.1%) cases it was indeterminate. TST was analyzed in two cut off values. Firstly, it was accepted positive if it is equal or above 10 (TST 1 ). A secondary analysis using a cut-off of 5 mm (TST 2 ) was done. TST 1 was positive in 42 (43.8%) cases. However, TST 2 was positive in 56 (58.3%) cases. Even though the gender had no effect on the results of QFT-G and TST 1, TST 2 was significantly positive in male cases. QFT-G was significantly more positive in BCG non vaccinated cases, but BCG vaccination did not affect the result of TSTs. Longer dialysis period was associated with positive TST results and QFT-G test was significantly more positive in older cases. However, there was no association between QFT-G test or TST results and parameters such as creatinin, kt/v, urea, ferritine, C-reactive protein and hemoglobin levels of the patients. The results of TST 1, TST 2 and QFT-G with respect to gender and BCG vaccination status were shown in Table 1. The overall concordance between QFT-G test and TST 1 was 71.9% (κ=0.427) and it was 61.5% between QFT-G test and TST 2 (κ=0.247). In 67 (69.7%) of 96 patients who had been BCG vacci- TABLE 1 - The results of TST 1, TST 2 and QFT-G with respect to gender and BCG vaccination status. TST 1 - positive TST 2 - positive QFT-G - positive n % p n % p n % p Gender BCG Female 17/ / / Male 25/ / / Negative 13/ / / Positive 29/ / / TST: tuberculin skin test; TST1: positive if it is equal or above 10 mm; TST2: positive if it is equal or above 5 mm; QFT-G: Quantiferon Gold.
4 354 E. Maden, T. Bekci, R. Kesli, H. Atalay, T. Teke, Y. Solak, S. Turk, K. Uzun TABLE 2 - The agreement between TST and QFT-G in BCG vaccinated cases and non vaccinated cases. BCG vaccinated BCG non-vaccinated (%) κ 95% CI (%) κ 95% CI QFT-G vs TST QFT-G vs TST QFT-G: Quantiferon-TB Gold; κ: kappa statistic; 95% CI: 95% confidence interval; TST: tuberculin skin test TST1: positive if it is equal or above 10 mm; TST2: positive if it is equal or above 5 mm. nated, TST 1 was positive in 26 (40.6%), TST 2 was positive in 40 (41.7%) and QFT-G test was positive in 21 (35%) cases. In 3 cases with BCG vaccination QFT-G test was indeterminate. When we omit these 3 cases and analyze the agreement between TST 1 and QFT-G, and the agreement between TST 2 and QFT-G in 64 BCG vaccinated cases, we found that the agreement between TST 1 and QFT-G was moderate (κ=0.432), and the agreement between TST 2 and QFT-G was fair (κ=0.229) (Table 2). In non vaccinated 29 cases; TST 1 was positive in 12 (42.4%), TST 2 was positive in 16 (55.2%) and QFT-G test was positive in 17 (58.6%) cases. QFT-G test was not indeterminate in any of these cases. In these 29 BCG non vaccinated cases, the overall agreement between TST 1 and QFT-G, and the agreement between TST 2 and QFT-G were both fair (κ=0.322, and κ=0.228, respectively) (Table 2). In this study, we found fair to moderate agreements between QFT-G test and TST in either a TST cut off value of 5 mm and 10 mm in cases with renal failure receiving HD. In previous studies determining the performances of QFT-G test versus the TST for detecting LTBI in ESRD cases, the agreement between these tests were variable. However, the agreement was not better than a fair result. In a recent study from Turkey, (Seyhan et al., 2009) reported an overall agreement of 65% (concordance κ=0.26) between the QFT-G and the TST at a cut off value of 10 mm. Lee et al. (2009) reported the overall agreement between QFT-G and TST as fair (κ=0.34) when the TST cut off was defined as 5 mm and fair (κ=0.25) when it was defined as 10 mm. They concluded that the QFT-G was a more accurate method for identifying those truly infected with Mycobacterium tuberculosis, even in BCG-vaccinated individuals. Also, the agreement between TST and QFT-G was poor (κ=0.16, p=0.116) in Triverio et al. (2009) study. They defined TST positive if an induration diameter was >5 mm and found that QFT-G was twice as effective at detecting probable LTBI (46%) as TST (25%). Another study (Winthrop et al., 2008) tested 100 patients with ESRD who received hemodialysis and they reported that QFT-G and T-SPOT-TB might offer a better method for detecting TB infection in ESRD patients. Inoue et al. (2008) reported that the sensitivity of the QFT was 100% and the specificity was 89.7% in hemodialysis patients. In our study, the positivity of QFT-G was similar to these studies (39.6%). However, TST positivity differed according to cut off value. When we defined a positive TST as an induration 5 mm, the positivity (58.3%) was significantly higher than QFT-G; but when we defined it as an induration 10 the positivity rate decreased to 43.8%. We found that, BCG vaccination had no effect on TST result. However, interestingly QFT- G was significantly more positive in BCG nonvaccinated cases. In previous studies reported from our country revealed a BCG vaccination rate between 77.6% to 90% (Soysal et al., 2008, Ozdemir et al., 2007, Elbek et al., 2009). In our study the rate of BCG vaccination was 69.7%. In our study, only age of the patient was associated with positive QFT-G result and dialysis duration was associated with positive TST results. As reported in previous studies nosocomial transmission of TB may occur in patients under long-term dialysis (Hickstein et al., 2003). This may be the reason of positive association of dialysis duration and positive TST. Similar to our study, Passalent et al. (2007) found that in patients with end-stage renal disease undergoing dialysis, a positive T-SPOT.TB was strongly associated with age.
5 Quantiferon assay and tuberculin skin test in end stage renal disease patients 355 There is no diagnostic gold standard for LTBI. So, we could not assess the sensitivity and specificity of QFT-G for this disease state. The only diagnostic standard for LTBI is the eventual development of active TB, and the predictive value for progression of TB can be ascertained only through longitudinal cohort studies that follow clinical outcomes of tested individuals. In the study reported by Diel R et al. (2008), they showed that QFT-G is a more accurate indicator of the presence of LTBI than the TST and provides at least the same sensitivity for detecting individuals who will progress to active TB. Also, high sensitivity and specificity of QFT-G tests in active tuberculosis disease is reported. In a meta-analysis done by Pai and O Brien (2008) revealed that the pooled sensitivity was 78% (CI, 73% to 82%) for QuantiFERON-TB Gold, and 70% (CI, 63% to 78%) for QuantiFERON-TB Gold In-Tube. The pooled specificity for both QuantiFERON tests was 99% among non BCG-vaccinated participants (CI, 98% to 100%) and 96% (CI, 94% to 98%) among BCG-vaccinated participants. They concluded that the Interferon gamma release assays (IGRAs), especially QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube, have excellent specificity that is unaffected by BCG vaccination. In conclusion, QFT-G test shows fair to moderate agreement with TST and it could be used in screening of LTBI simultaneously with TST; but their relatively high cost and need for laboratory infrastructure is a limitation of QFT-G tests and to analyze the use of it alone in screening of LT- BI in cases with ESRD receiving hemodialysis larger long-follow up studies are needed. The study was conducted in Selcuk University Meram Medical Faculty and in Konya Research and Education Hospital. There is no conflict of interest related to this research and there is no financial support from any institution. REFERENCES AMERICAN THORACIC SOCIETY (ATS) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). (2000). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161, S221-S247. AMICOSANTE M., CICCOZZI M., MARKOVA R. (2010). Rational use of immunodiagnostic tools for tuberculosis infection: guidelines and cost effectiveness studies. New Microbiol. 33, ANDREW O.T., SCHOENFELD P.Y., HOPEWELL P.C. (1980). Tuberculosis in patients with end-stage renal disease. Am. J. Med. 68, 59. CENGIZ K. (1996). Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron. 73, 421. DIEL R., LODDENKEMPER R., MEYWALD-WALTER K., NIEMANN S., NIENHAUS A. (2008). Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 177, ELBEK O., UYAR M., AYDIN N., BÖREKÇI S., BAYRAM N., BAYRAM H., DIKENSOY O. (2009). Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin. Rheumatol. 28, HICKSTEIN L., MCPHERSON C., KWALICK D. (2004). Tuberculosis transmission in a renal dialysis center. Nevada, MMWR. 53, HUSSEIN M.M., MOOIJ J.M., ROUJOULEH H. (2003). Tuberculosis and chronic renal disease. Semin. Dial. 16, 38. INOUE T., NAKAMURA T., KATSUMA A., MASUMOTO S., MINAMI E., KATAGIRI D. (2009). The value of QuantiFERON TB-Gold in the diagnosis of tuberculosis among dialysis patients. Nephrol. Dial. Transplant. 24, JONES S., DE GIJSEL D., WALLACH F.R., GURTMAN A.C., SHI Q., SACKS H. (2007). Utility of QuantiFERON- TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int. J. Tuberc. Lung. Dis. 11, KOBASHI Y., MOURI K., OBASE Y. (2007). Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur. Respir. J. 30, KÜRS AT S., OZGÜR B. (2001). Increased incidence of tuberculosis in chronic hemodialysis patients. Am. J. Nephrol. 21, KURTZ P., KOHLER H., MENER S. (1986). Impaired cellular immune responses in chronic renal failure: Evidence for a T-cell defect. Kidney Int. 29, LEE S.S.J., CHOU K.J., SU I.J., CHEN Y.S. (2009). High Prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection. 37, LEUNG C.C., YAM W.C., YEW W.W., HO P.L., TAM C.M., LAW W.S. (2008). Comparison of T-Spot.TB and tuberculin skin test among silicotic patients. Eur. Respir. J. 31,
6 356 E. Maden, T. Bekci, R. Kesli, H. Atalay, T. Teke, Y. Solak, S. Turk, K. Uzun LUETKEMEYER A.F., CHARLEBOIS E.D., FLORES L.L., BANGSBERG D.R., DEEKS S.G., MARTIN J.N. (2007). Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am. J. Respir. Crit. Care Med. 175, MENZIES D., PAI M., COMSTOCK G. (2007). Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann. Intern. Med. 146, MITWALLI A. (1991). Tuberculosis in patients on maintenance dialysis. Am. J. Kidney Dis. 18, OZDEMIR D., ANNAKKAYA A.N., TARHAN G., SENCAN I., CESUR S., BALBAY O., GUCLU E. (2007). Comparison of the tuberculin skin test and the quantiferon test for latent Mycobacterium tuberculosis infections in health care workers in Turkey. Jpn. J. Infect. Dis. 60, PAI M., O BRIEN R. (2008). Review of T-cell based assays for the diagnosis of latent tuberculosis infection. Ann. Intern. Med. 149, PASSALENT L., KHAN K., RICHARDSON R. (2007). Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T- SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin. J. Am. Soc. Nephrol. 2, PIANA F., CODECASA L.R., CAVALLERIO P. (2006). Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur. Respir. J. 28, RAVI SHANKAR M.S., ARAVINDAN A.N., SOHAL P.M. (2005). The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol. Dial. Transplant. 20, SEYHAN E.C., SÖKÜCÜ S., ALTIN S. (2009). Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection in hemodialysis patients. Transpl. Infect. Dis. 10 (Epub ahead of print). SMIRNOFF M., PATT C., SECKLER B. (1998). Tuberculin and anergy skin testing of patients receiving longterm hemodialysis. Chest. 113, SOYSAL A., TORUN T., EFE S., GENCER H., TAHAOGLU K., BAKIR M. (2008). Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M. tuberculosis infection. Int. J. Tuberc. Lung. Dis. 12, TRIVERIO P.A., BRIDEVAUX P.O., ROUX-LOMBARD P., NIKSIC L., ROCHAT T., MARTIN P.Y. (2009). Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol. Dial. Transplant. 24, VIERA A.J., GARRETT J.M. (2005). Understanding interobserver agreement: the kappa statistic. Fam. Med. 37, WINTHROP K.L., NYENDAK M., CALVET H., OH P., LO M., SWARBRICK G. (2008). Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. Clin. J. Am. Soc. Nephrol. 3, WOELTJE K.F., MATHEW A., ROTHSTEIN M., SEILER S., FRASER V.J. (1998). Tuberculosis infection and anergy in hemodialysis patients. Am. J. Kidney. Dis. 31,
Should IGRAs replace the TST?
Should IGRAs replace the TST? Jim Rothel Melbourne, Australia Disclaimer: I am a consultant to Cellestis, a QIAGEN company Presentation Outline Comparative performance of QFT and the TST Is the TST / QFT
More informationIGRAs for Serial Testing of Healthcare Workers
IGRAs for Serial Testing of Healthcare Workers Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding
More informationQuantiferon Assay versus Tuberculin Skin Test in Detection of Latent TB Among Patients on Haemodialysis
Science Journal of Medicine & Clinical Trial ISSN:2276-7487 http://www.sjpub.org/sjmct.html Author(s) 2013. CC Attribution 3.0 License. Research Article Published By Science Journal Publication International
More informationInterferon Gamma Release Assays (IGRAs) for the Diagnosis of Latent Tuberculosis Infection. Conflict of interest statement.
Interferon Gamma Release Assays (IGRAs) for the Diagnosis of Latent Tuberculosis Infection Conflict of interest statement I have performed, and am currently performing, studies using the T-Spot. TB IGRA
More informationUpdated CDC Guidelines for Interferon Gamma Release Assays
TB Intensive San Antonio, Texas August 2-5, 2011 Updated CDC Guidelines for Interferon Gamma Release Assays Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to
More informationScreening children for TB in Europe. Professor Beate Kampmann FRCPCH, PhD. Imperial College, London & MRC Unit- The Gambia
Screening children for TB in Europe Professor Beate Kampmann FRCPCH, PhD Imperial College, London & MRC Unit- The Gambia 21. Tuberkulose-Symposium Mu nchenwiler 22. Ma rz 2012 Acknowledgement Presentation
More informationIGRA: Diagnosing TB in the Twenty-First Century with. Peter Barnes, MD
TB Intensive Tyler, Texas June 2-4, 2010 IGRA: Diagnosing TB in the Twenty-First Century with Case Studies Peter Barnes, MD June 4, 2010 Interferon Gamma Releasing Assays: Diagnosing TB in the Twenty-First
More informationChanging the way the world looks at TB
Changing the way the world looks at TB QuantiFERON -TB Gold www.quantiferon.com Identifying TB Infection is essential Tuberculosis (TB) remains a significant threat to humanity. At least one billion people
More informationTwo Interferon Gamma Release Assays and Tuberculin Skin Test in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia
Two Interferon Gamma Release Assays and Tuberculin Skin Test in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia Ifedayo Adetifa,Martin Ota, Abdulrahman Hammond, Moses Lugos,Owiafe
More informationInterferon Gamma Release Assay and Tuberculin Skin Test in the Diagnosis of Latent Tuberculosis among Health Care Workers A Comparative Study
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 6 (2017) pp. 2360-2368 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.606.280
More informationDIAGNOSIS OF TB D R. K O N G P O M A R N K O N G C L I N I C F O R C H E S T & I N T E R N A L M E D I C I N E
DIAGNOSIS OF TB D R. K O N G P O M A R N K O N G C L I N I C F O R C H E S T & I N T E R N A L M E D I C I N E PATHOGENESIS OF TB INFECTION AND DISEASE (I) PATHOGENESIS OF TB INFECTION AND DISEASE (II)
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gao L, Lu W, Bai L, et al, for the LATENTTB-NSTM
More informationLTBI Testing: Areas of Concern and Gray Zones
LTBI Testing: Areas of Concern and Gray Zones June 2, 2015 Masa Narita, MD Outline Positive Predictive Value LTBI testing in the general population Reproducibility Boosting Positive Predictive Value The
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 Updated CDC Guidelines for Interferon Gamma Release Assays Phil LoBue, MD, FACP, FCCP; CDC December 1, 2010 Update on Interferon-γ Release Assays Philip
More informationDepartment of Medical Statistics, Leiden University Medical Center, Leiden, The. KNCV Tuberculosis Foundation, The Hague, The Netherlands
CVI Accepts, published online ahead of print on August 00 Clin. Vaccine Immunol. doi:0./cvi.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationEvaluating Diagnostic Tests in the Absence of a Gold Standard
Evaluating Diagnostic Tests in the Absence of a Gold Standard Nandini Dendukuri Departments of Medicine & Epidemiology, Biostatistics and Occupational Health, McGill University; Technology Assessment Unit,
More informationUsefulness of Tuberculin Skin Test and Three Interferon-Gamma Release Assays for the Differential Diagnosis of Pulmonary Tuberculosis
ORIGINAL ARTICLE Usefulness of Tuberculin Skin Test and Three Interferon-Gamma Release Assays for the Differential Diagnosis of Pulmonary Tuberculosis Yoshihiro Kobashi, Masaaki Abe, Keiji Mouri, Yasushi
More informationScreening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions
EXTENDED REPORT Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions S Kleinert, 1 H-P Tony, 1 K Krueger, 2 J Detert,
More informationEVALUATION OF LATENT TUBERCULOSIS INFECTION SCREENING IN THE FIELD
EVALUATION OF LATENT TUBERCULOSIS INFECTION SCREENING IN THE FIELD Gema Morales Meyer DNP, RN, APHN BC, CNS Penny Weismuller DrPH, RN Presenter Disclosures Gema Morales Meyer DNP, RN, APHN BC, CNS The
More informationDiagnosis of Latent TB Infection
Diagnosis of Latent TB Infection Patricio Escalante, MD, MSc, FCCP Division of Pulmonary and Critical Care Medicine Mycobacterial and Bronchiectasis Clinic Olmsted County Tuberculosis Clinic Mayo Clinic
More informationStatistical approaches for dealing with imperfect reference standards
Statistical approaches for dealing with imperfect reference standards Nandini Dendukuri Departments of Medicine & Epidemiology, Biostatistics and Occupational Health, McGill University; Technology Assessment
More informationPredicting Progression to Tuberculosis Disease in Young Children. Amina Ahmed, MD Levine Children s Hospital March 2, 2018
Predicting Progression to Tuberculosis Disease in Young Children Amina Ahmed, MD Levine Children s Hospital March 2, 2018 Children Are Our Future Diagnosis and treatment of latent tuberculosis infection
More informationQuantiFERON -TB Gold In-Tube:
QuantiFERON -TB Gold In-Tube: A 7-year Experience at the Bellvitge University Hospital. Dr. Miguel Santín Department of Infectious Diseases Bellvitge University Hospital University of Barcelona 2nd Symposium
More informationIGRAs in Diagnosis of Childhood LTBI and Active TB: Yes
IGRAs in Diagnosis of Childhood LTBI and Active TB: Yes Professor Ajit Lalvani Director, Tuberculosis Research Unit National Heart and Lung Institute Imperial College London Conflict of Interest Statement:
More informationDisclosures. Serial Tes+ng for TB Infec+on with IGRAs: Understanding the Sources of Variability. Stanford Hospital Policy
Serial Tes+ng for TB Infec+on with IGRAs: Understanding the Sources of Variability Disclosures Banaei: No financial conflicts No industry links or funding Niaz Banaei MD Assistant Professor of Pathology
More informationTuberculin Skin Test and Boosted Reactions among Newly Employed Healthcare Workers: An Observational Study
Tuberculin Skin Test and Boosted Reactions among Newly Employed Healthcare Workers: An Observational Study Song Yee Kim 1, Moo Suk Park 1, Young Sam Kim 1, Se Kyu Kim 1, Joon Chang 1, Dongeun Yong 2, Hyun
More informationwarwick.ac.uk/lib-publications
Original citation: Auguste, Peter, Tsertsvadze, Alexander, Court, Rachel A. and Pink, Joshua. (2016) A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying
More informationThe Second Global Symposium on IGRAs June 1, 2009
Akiko Kowada, MD PhD Director, Department of Health Service Katsushika City Public Health Center, Tokyo, Japan The Second Global Symposium on IGRAs June 1, 2009 Overview Background Study 1: Cost effectiveness
More informationThorax Online First, published on June 12, 2012 as /thoraxjnl Tuberculosis
Thorax Online First, published on June 12, 2012 as 10.1136/thoraxjnl-2011-201542 Tuberculosis < Additional materials are published online only. To view these files please visit the journal online (http://thorax.bmj.
More informationJohn Metcalfe, MD, MPH Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, and Curry International Tuberculosis Center
WITHIN TEST TEST VARIABILITY OF THE QUANTIFERON TB TB GOLD IN TUBE ASSAY IN A LARGE COHORT OF LOW RISK SUBJECTS John Metcalfe, MD, MPH Division of Pulmonary and Critical Care Medicine, San Francisco General
More informationFAQs for Laboratory Professionals
FAQs for Laboratory Professionals QuantiFERON -TB Gold Plus Sample to Insight Contents Questions and answers 3 Test principle 3 Blood collection 4 The blood hasn t reached the black mark on the side of
More informationInterferon-c release assays do not identify more children with active tuberculosis than the tuberculin skin test
Eur Respir J 2009; 33: 1374 1382 DOI:.1183/09031936.00153408 Copyright ERS Journals Ltd 2009 Interferon-c release assays do not identify more children with active tuberculosis than the tuberculin skin
More informationTitle: Mantoux Tuberculin Test Number: TCFHT-MD14 Activation Date: 09-Sep-2014 Review Date: 09-Sep-2015
MEDICAL DIRECTIVE Mantoux Tuberculin Test Number: TCFHT-MD14 Activation Date: 09-Sep-2014 Review Date: 09-Sep-2015 Sponsoring/Contact Person(s) (name, position, contact particulars): Victoria Paulionis,
More informationIt s the BIG DAY! Preparing for your New Hire s First Day
It s the BIG DAY! Preparing for your New Hire s First Day Properly preparing for the arrival of a new hire to your location is very similar to preparing for your new arrival(s) in your personal life. You
More informationSouthern California CSU DNP Consortium
Southern California CSU DNP Consortium California State University, Fullerton California State University, Long Beach California State University, Los Angeles EVALUATION OF LATENT TUBERCULOSIS INFECTION
More informationTitle: Avoiding the effect of BCG-vaccination in detecting MTB infection with a
ERJ Express. Published on February 15, 2006 as doi: 10.1183/09031936.06.00107005 Title: Avoiding the effect of BCG-vaccination in detecting MTB infection with a blood test Short title: MTB contact investigation
More informationAbout OMICS Group Conferences
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of
More informationRapid diagnostic tests for the detection of tuberculosis infection. Centre for Statistics in Medicine, University of Oxford, UK 3
Rapid diagnostic tests for the detection of tuberculosis infection A systematic review of rapid diagnostic tests for the detection of tuberculosis infection J Dinnes, 1* J Deeks, 2 H Kunst, 3 A Gibson,
More informationORIGINAL INVESTIGATION. Cost-effectiveness of Interferon Gamma Release Assays vs Tuberculin Skin Tests in Health Care Workers. (HCWs) are at increased
ORIGINAL INVESTIGATION Cost-effectiveness of Interferon Gamma Release Assays vs Tuberculin Skin Tests in Health Care Workers Marie A. de Perio, MD; Joel Tsevat, MD, MPH; Gary A. Roselle, MD; Stephen M.
More informationFAQs for Laboratory Professionals. QuantiFERON -TB Gold
FAQs for Laboratory Professionals QuantiFERON -TB Gold Questions and answers These Frequently Asked Questions (FAQs) relate to the QuantiFERON -TB Gold (QFT ) assay. The answers provided are meant to act
More information3) Use of TST or QFT-G is recommended (not both). Persons with a documented prior positive TST or QFT-G result do not need to be retested.
Notes for Algorithms 1) Management of contacts to XDR-TB patients is complex and largely based on expert opinion. Individual patient decisions may need to vary from these algorithms based on individual
More informationScreening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice
Open Access To cite: Eralp MN, Scholtes S, Martell G, et al. Screening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice. BMJ Open 2012;2:
More informationBMC Research Notes. Open Access. Abstract
BMC Research Notes BioMed Central Short Report IGRA tests perform similarly to TST but cause no adverse reactions: pediatric experience in Finland Esko Tavast* 1,4, Eeva Salo 2, Ilkka Seppälä 1,3 and Tamara
More informationIGRAs Utility in high and low burden settings NDWG meeting, Lille, 2011
IGRAs Utility in high and low burden settings NDWG meeting, Lille, 2011 Keertan Dheda, MB.BCh, FCP(SA), FCCP, FRCP (Lond), PhD (Lond) Professor and Head: Lung Infection and Immunity Unit Division of Pulmonology
More informationjmb A Homogeneous Immunoassay Method for Detecting Interferon- Gamma in Patients with Latent Tuberculosis Infection Research Article Review
J. Microbiol. Biotechnol. (2016), 26(3), 588 595 http://dx.doi.org/10.4014/jmb.1507.07102 Review Research Article jmb A Homogeneous Immunoassay Method for Detecting Interferon- Gamma in Patients with Latent
More informationChapter XIII. USRDS Research Studies. Appreciation Of Renal Community Participation. Ongoing USRDS Special Studies
Chapter XIII T he USRDS conducts two different kinds of studies: Existing Data Studies and Special Studies. Existing Data Studies analyze data that already have been collected; these studies will be discussed
More informationOriginal Article INTRODUCTION. Wonju , Korea 2 Institute of Life Science and Biotechnology, Yonsei University, Seoul , Korea
J. Exp. Biomed. Sci. 013, 19(): 90~97 pissn : 1738-36 Original Article Comparison of Mycobacterium tuberculosis Specific Antigen Stimulation Time for Performing Interferon Gamma mrna Assay for Detecting
More informationUpdate on the TESEC trials Development of a novel Mtb skin test
ESM Brasov 2012 TALLER UITB-2013 Update on the TESEC trials Development of a novel Mtb skin test Søren Tetens Hoff MD, PhD. Research Scientist Human Immunology Department of Infectious Disease Immunology
More informationInterpretation and Clinical Correlation of Tuberculin Skin Test Results among Clinically Diagnosed Childhood Tuberculosis
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Interpretation and Clinical Correlation of Tuberculin Skin Test Results among Clinically Diagnosed Childhood Tuberculosis
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationNasser AE. AIHamdan 1 ; Moustafa A.F. Abbas 1,2, Mohamed S. AIQahtani 3 Suhail Klantan 3 ; Lamiaa A.Fiala 2 and Gehad ElGhazali 3,4
Comparison of Tuberculin Skin Test (TST) and Quantiferon Test (QFT) for detection of Latent TB infection among Health Care Workers (HCWs) in a Tertiary Care Hospital in Riyadh, Saudi Arabia. Nasser AE.
More informationMycobacterial transport medium for routine culture of fine needle aspiration biopsies
Mycobacterial transport medium for routine culture of fine needle aspiration biopsies C A Wright, A Vermaak Divisions of Anatomical Pathology, Department of Pathology, Stellenbosch University and NHLS
More informationScreening of Health Care Workers for Tuberculosis: Development and Validation of a New Health Economic Model to Inform Practice For peer review only
Screening of Health Care Workers for Tuberculosis: Development and Validation of a New Health Economic Model to Inform Practice Journal: BMJ Open Manuscript ID: bmjopen-0-000 Article Type: Research Date
More informationDiscordance of Tuberculin Skin Test and Interferon Gamma Release Assay in Recently Exposed Household Contacts of Pulmonary TB Cases in Brazil
Discordance of Tuberculin Skin Test and Interferon Gamma Release Assay in Recently Exposed Household Contacts of Pulmonary TB Cases in Brazil Rodrigo Ribeiro-Rodrigues 1, Soyeon Kim 2, Flávia Dias Coelho
More informationPaediatrica Indonesiana. Using iron profiles to identify anemia of chronic disease in anemic children with tuberculosis
Paediatrica Indonesiana VOLUME 51 July NUMBER 4 Original Article Using iron profiles to identify anemia of chronic disease in anemic children with tuberculosis Reni Wigati, Endang Windiastuti, Badriul
More informationMay Billing and Compliance. Hematology. Immunohistochemistry. Immunology. Microbiology. Referral Testing. Supplies
May 2018 Billing and Compliance Glomerular basement membrane, IgG assay CPT code Hematology Differential reporting changes Immunohistochemistry Anaplastic lymphoma kinas (ALK) therapeutic update Multiple
More informationManagement of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested
More informationSystems approaches to new vaccines and diagnostics for bovine tuberculosis Johnjoe McFadden
Systems approaches to new vaccines and diagnostics for bovine tuberculosis Johnjoe McFadden Vaccine Development The Traditional approach Live cells Dead cells Cellular subunits Protective immune response
More informationTHE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 21 (2): 2014 Page: 75-83
THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 21 (2): 2014 Page: 75-83 Assessment of T Cell Response to Novel Mycobacterium tuberculosis Synthetic Overlapping Peptides Mixtures (Rv2659 and Rv2660) and ESAT-6
More informationHSV-2 therapeutic vaccine program. Subunit vaccine candidates
HSV-2 therapeutic vaccine program Subunit vaccine candidates Our HSV-2 vaccine program Therapeutic subunit vaccine T-cell-based Aim: Best-in-class antigens by engineering Excellent standing (Sept 2017):
More informationDevelopment and Evaluation of an Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Bovine Tuberculosis
Development and Evaluation of an Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Bovine Tuberculosis Ralph Lausterer, Roland Hardegger, Patrick Mossi, Alex J. Raeber Thermo Fisher Scientific,
More informationOperational Issues with Implementation of QuantiFERON TB Gold Testing in Iowa. Michael Pentella, Ph.D., D(ABMM), CIC University Hygienic Lab
Operational Issues with Implementation of QuantiFERON TB Gold Testing in Iowa Michael Pentella, Ph.D., D(ABMM), CIC University Hygienic Lab http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5711a2.htm How did
More informationParadigm for Translation of Infectious Disease Products
Paradigm for Translation of Infectious Disease Products Colorado State University, Fort Collins, CO NIH, NIAID Contract NO1-AI-25469 Part I - Leprosy Research Support Leprosy Skin Test Study Develop improved
More informationIP-10 is a sensitive biomarker of antigen recognition in whole blood stimulation
CVI Accepted Manuscript Posted Online 24 June 2015 Clin. Vaccine Immunol. doi:10.1128/cvi.00324-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 1 2 3 IP-10 is a sensitive biomarker
More informationTUBERCULOSIS (TB) IS THE SINGLE
ORIGINAL CONTRIBUTION Comparison of a Whole-Blood Interferon Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium tuberculosis Infection Gerald H. Mazurek, MD Philip A. LoBue, MD Charles
More informationFor personal use only
ADMEDUS Ltd ABN 35 088 221 078 REGISTERED OFFICE: Level 1, 197 Adelaide Terrace Perth Western Australia 6000 PO Box 6879 East Perth Western Australia 6892 ASX ANNOUNCEMENT T +61 (0)8 9266 0100 F +61 (0)8
More informationUse of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey
VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research
More informationLabs, Ledgers, and Lives Saved: The Impact of Diagnostic Strategies on the Epidemiology and Economics of Tuberculosis
Labs, Ledgers, and Lives Saved: The Impact of Diagnostic Strategies on the Epidemiology and Economics of Tuberculosis David Dowdy, MD, PhD 9 th National Conference on Laboratory Aspects of Tuberculosis
More informationMaterial & Labor Costs
Online supplement to: Screening Healthcare Workers with IGRA vs. TST: Impact on Costs and Adherence to Testing (the SWITCH study) This supplement shows the material and labour costs at our institution
More informationSerum Ceruloplasmin Albumin Ratio as A Marker of Treatment Response in Pulmonary Tuberculosis
ORIGINAL ARTICLE Serum Ceruloplasmin Albumin Ratio as A Marker of Treatment Response in Pulmonary Tuberculosis Jemil S. Makadia 1*, Anju Jain 2 1 MD Biochemistry, Biochemistry department, B J Medical College,
More informationEnhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany
Respiratory Medicine (2009) 103, 1838e1853 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention
More informationVACCINE AND TB SKIN TEST INFORMATION
VACCINE AND TB SKIN TEST INFORMATION Please click on the appropriate link below to obtain vaccine and TB skin test information for the Health Science programs. Questions? Call the appropriate program director/coordinator
More informationEnhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany
Respiratory Medicine (2009) xx, 1e16 ARTICLE IN PRESS available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Enhanced cost-benefit analysis of strategies for LTBI screening and
More informationQuarters 3-4, 2016 & Annual Data provisional 8 th March 2017
Version 1.0 Page 1 of 6 Invasive Pneumococcal Disease in Ireland Bi-annual report by the Health Protection Surveillance Centre Irish Pneumococcal Reference Laboratory, Temple Street Children s University
More informationEvidence-based TB Diagnosis: how evidence informs practice and policy Madhukar Pai, MD, PhD
Evidence-based TB Diagnosis: how evidence informs practice and policy Madhukar Pai, MD, PhD Assistant Professor, McGill University, Montreal Co-Chair, Evidence Subgroup, New Diagnostics Working Group 1
More informationRapid Detection of Tuberculosis using Magnetic Nanotechnology Particles (MNPs) in Peru. Jacob Shermetaro, OMS-II
Rapid Detection of Tuberculosis using Magnetic Nanotechnology Particles (MNPs) in Peru Jacob Shermetaro, OMS-II Rapid Detection of Tuberculosis using Magnetic Nanotechnology Particles (MNPs) in Peru Jacob
More informationSetting The setting was a hospital. The economic study was carried out in Besancon University hospital, France.
Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit Tissot E, Woronoff-Lemsi M C, Cornette C, Plesiat P, Jacquet M, Capellier
More informationAn aid in the diagnosis of tuberculosis infection PACKAGE INSERT. For In Vitro Diagnostic Use. This Package Insert covers use of:
An aid in the diagnosis of tuberculosis infection PACKAGE INSERT For In Vitro Diagnostic Use This Package Insert covers use of: T-SPOT.TB 8 (Multi-use 8-Well Strip Plate Format. Catalogue number: TB.300)
More informationMIC1-MAG1-SAG1 chimeric protein, a most effective antigen for detection of human
CVI Accepts, published online ahead of print on 3 October 2012 Clin. Vaccine Immunol. doi:10.1128/cvi.00452-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 MIC1-MAG1-SAG1
More informationAchievement Level Descriptors for Medical Interventions
Achievement Level Descriptors for Medical Interventions Achievement Level Descriptors (ALDs) are statements of what students should know and be able to do in a PLTW classroom. The ALDs can be used to better
More informationi) Wild animals: Those animals that do not live under human supervision or control and do not have their phenotype selected by humans.
The OIE Validation Recommendations provide detailed information and examples in support of the OIE Validation Standard that is published as Chapter 1.1.6 of the Terrestrial Manual, or Chapter 1.1.2 of
More informationEUROPEAN COMMISSION HEALTH & FOOD SAFETY. Directorate G Veterinary and International affairs. Unit G2- Animal health
EU-RL for Bovine Tuberculosis Ref. Ares(2016)855831 VISAVET v4-18/02/2016 EUROPEAN COMMISSION HEALTH & FOOD SAFETY Directorate G Veterinary and International affairs Unit G2- Animal health EUROPEAN UNION
More informationTuberculosis (TB) is an important public
Eur Respir J 2010; 35: 851 857 DOI: 10.1183/09031936.00067209 CopyrightßERS Journals Ltd 2010 Nested PCR in lung tissue for diagnosis of pulmonary tuberculosis J.S. Park*, Y.A. Kang*, S.Y. Kwon*, H.I.
More informationThe Laboratory s Role in TB Diagnosis and Treatment
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 The Laboratory s Role in TB Diagnosis and Treatment EDWARD BANNISTER, Ph.D. December 9, 2009 The Laboratory s Role in TB Diagnosis and Treatment
More informationAbstract. Introduction. imedpub Journals
Short Communication imedpub Journals www.imedpub.com Journal of Scientific and Industrial Metrology ISSN 2472-1948 DOI: 10.21767/2472-1948.100003 Influence of the Spectrophotometer on Readings and Results
More informationBarriers on implementation of rapid methods of TB diagnosis
Barriers on implementation of rapid methods of TB diagnosis Turid Mannsåker National Reference Laboratory for Mycobacteria Norwegian Institute of Public Health TB in Norway around 1900: Among the highest
More informationSynagis (Palivizumab) Drug Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Synagis (Palivizumab) Drug Prior Authorization Protocol This policy has been developed through review of medical
More informationOHM MODULES. Appointment Scheduler. Billing Manager. For more information call or visit ULehssustainability.com/ohm
OHM MODULES Occupational Health Manager (OHM) is a multi-module software solution that gives you all the detailed tracking and reporting tools you need to streamline information management, maximize consistency
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 Genotyping Lisa Armitige, MD, PhD May 08, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant financial
More informationMycobacterium tuberculosis, a highly successful parasite, is the
Evaluation of Gamma Interferon Immune Response Elicited by the Newly Constructed PstS-1(285-374):CFP10 Fusion Protein To Detect Mycobacterium tuberculosis Infection Leonardo Silva de Araujo, a Fernanda
More informationDetect single-cell secretion with ELISpot
Detect single-cell secretion with ELISpot ELISpot is a sensitive assay used to quantify cytokine- or immunoglobulin-secreting cells at the single-cell level. ELISpot has been widely applied to investigate
More informationShort- and Long-Term Immune Responses of CD-1 Outbred Mice to the Scrub Typhus DNA Vaccine Candidate: p47kp
Short- and Long-Term Immune Responses of CD-1 Outbred Mice to the Scrub Typhus DNA Vaccine Candidate: p47kp GUANG XU, a SUCHISMITA CHATTOPADHYAY, a JU JIANG, a TEIK-CHYE CHAN, a CHIEN-CHUNG CHAO, a WEI-MEI
More informationFind 1 cell in 100,000 with ELISpot
Find 1 cell in 100,000 with ELISpot ELISpot is a sensitive assay used to quantify cytokine- or immunoglobulin-secreting cells at the single-cell level. ELISpot has been widely applied to investigate specific
More informationTuberculin skin test and ELISPOT/T. SPOT.TB in children and adolescents with juvenile idiopathic arthritis
Sztajnbok et al. Pediatric Rheumatology 2014, 12:17 RESEARCH Open Access Tuberculin skin test and ELISPOT/T. SPOT.TB in children and adolescents with juvenile idiopathic arthritis Flavio Sztajnbok 1*,
More informationVersion 1.0v Page 1 of 5 Invasive Pneumococcal Disease in Ireland
Version 1.0v Page 1 of 5 Invasive Pneumococcal Disease in Ireland A Bi-annual report by the Health Protection Surveillance Centre and the Irish Pneumococcal Reference Laboratory at the Department of Clinical
More informationEvaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis
INT J TUBERC LUNG DIS 13(11):1416 1421 2009 The Union Evaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis D. R. Bienek,* C. K. Chang* * Naval
More informationDecember 18, 2014 Approval Letter - INTERCEPT Blood System for Platelets
Page 1 of 5 December 18, 2014 Approval Letter - INTERCEPT Blood System for Platelets December 18, 2014 Cerus Corporation Attn: Ms. Carol M. Moore 2550 Stanwell Drive Concord, CA 94520 APPROVAL ORDER Re:
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Genotyping Basics for the Clinician Lisa Armitige, MD, PhD Wednesday April 6,2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationWorkshop on flexible designs for diagnostic studies. from diagnostic accuracy to personalized medicine
Workshop on flexible designs for diagnostic studies from diagnostic accuracy to personalized medicine Structure Background Sources of error Summary 06/11/2017 Introduction 2 Structure Background Sources
More information